Alzheimer’s new treatment 2026 is no longer just a headline — it is a clinical reality changing lives for seniors diagnosed with early Alzheimer’s disease. Two groundbreaking drugs, Leqembi (lecanemab) and Donanemab (Kisunla), have received FDA approval and are now being administered in clinics across the country. If you or a loved one has been recently diagnosed with mild cognitive impairment or early Alzheimer’s, this guide explains everything you need to know right now.
What Are Leqembi and Donanemab? How Do They Work?
Both drugs belong to a class called anti-amyloid monoclonal antibodies. They target amyloid plaques — the sticky protein clumps in the brain that are a hallmark of Alzheimer’s disease. By clearing these plaques, the drugs aim to slow the progression of cognitive decline rather than simply masking symptoms.
Leqembi (lecanemab), developed by Eisai and Biogen, received full FDA approval in July 2023. It is given as an intravenous infusion every two weeks. Clinical trials showed it slowed cognitive decline by approximately 27% compared to placebo over 18 months — a meaningful effect that was statistically significant.
Donanemab (Kisunla), developed by Eli Lilly, received full FDA approval in July 2024. It is given monthly by IV infusion. The TRAILBLAZER-ALZ 2 trial showed it slowed decline by up to 35% in patients with low-to-medium tau protein levels. Notably, about 72% of participants were able to stop treatment after 12 months once their plaques were cleared — making it potentially a finite course of therapy rather than a lifelong treatment.
Who Qualifies for These Alzheimer’s Treatments in 2026?
These drugs are not for everyone with Alzheimer’s. They are specifically indicated for patients with early symptomatic Alzheimer’s disease, meaning mild cognitive impairment (MCI) due to Alzheimer’s, mild Alzheimer’s dementia (early stage), and confirmed amyloid pathology via PET scan or cerebrospinal fluid test. They are not appropriate for moderate or severe Alzheimer’s, as clinical evidence does not support use at those stages.
| Drug | Dosing | Trial Slowing of Decline | Duration |
|---|---|---|---|
| Leqembi (lecanemab) | IV every 2 weeks | ~27% | Ongoing (chronic) |
| Donanemab (Kisunla) | IV monthly | Up to 35% | ~12 months then stop |
Does Medicare Cover Leqembi and Donanemab in 2026?
Yes — this is the critical update for 2026. Medicare began covering FDA-approved anti-amyloid Alzheimer’s therapies under Medicare Part B following a revised National Coverage Determination (NCD). As of 2026, Medicare covers the drug infusion itself (80% after the $283 Part B deductible), required amyloid PET scans for confirmed diagnosis (one per patient), and monitoring MRIs for ARIA (brain swelling/bleeding).
Coverage requires that treatment be provided in a clinical setting and that the prescribing physician participate in a CMS-approved registry to monitor outcomes. Out-of-pocket costs under Original Medicare can be significant — approximately $5,000–$20,000 per year after the 20% coinsurance — making Medigap Plan G or a Medicare Advantage plan’s drug coverage important to review.
What Is ARIA — The Key Safety Risk Every Senior Must Understand
The most important safety concern with both drugs is ARIA (Amyloid-Related Imaging Abnormalities) — brain swelling (ARIA-E) or microbleeds (ARIA-H) detected on MRI scans. ARIA occurred in about 37% of Leqembi patients (most were asymptomatic), while symptomatic ARIA occurred in about 3%, and serious ARIA requiring hospitalization occurred in under 1%. APOE e4 gene carriers face higher ARIA risk. Because of this risk, regular MRI monitoring is mandatory throughout treatment.
How to Access These Treatments: 5 Steps for Seniors in 2026
- Get a formal cognitive evaluation — Ask your primary care doctor for a referral to a neurologist or memory center specializing in Alzheimer’s. Bring a family member who can describe changes they’ve noticed over time.
- Confirm amyloid pathology — An amyloid PET scan or cerebrospinal fluid (CSF) biomarker test is required before treatment. Medicare covers one amyloid PET per patient with appropriate documentation.
- Get genotyped for APOE e4 — Many centers recommend genetic testing before starting therapy. Having one or two copies of APOE e4 significantly increases ARIA risk and changes the risk-benefit calculation.
- Verify your Medicare coverage and out-of-pocket costs — Call 1-800-MEDICARE (1-800-633-4227) or visit Medicare.gov. Ask about manufacturer patient assistance programs if costs are prohibitive.
- Find a qualified infusion center — Use the Alzheimer’s Association helpline at 1-800-272-3900 to find certified treatment centers near you.
What These Drugs Can and Cannot Do
Slowing cognitive decline by 27–35% is genuinely significant — it may mean an extra 6–12 months of independence, clear communication with loved ones, and maintained dignity. However, these drugs do not cure Alzheimer’s disease and do not restore lost memory. They slow the progression. Research is accelerating rapidly, with combination therapies targeting tau protein, neuroinflammation, and synaptic health currently in clinical trials.
Lifestyle Strategies That Complement Drug Therapy
Whether or not you are a candidate for anti-amyloid therapy, these evidence-based strategies protect brain health: 150 minutes of moderate aerobic exercise per week (increases BDNF and reduces amyloid buildup); the MIND diet rich in leafy greens, berries, fish, olive oil, and nuts (associated with 21% lower dementia risk); 7–9 hours of quality sleep (the brain clears amyloid during deep sleep via the glymphatic system); blood pressure control under 130/80 (midlife hypertension is a major modifiable risk factor); and active social engagement and cognitive stimulation.
Sources
1. FDA — Leqembi (lecanemab) Prescribing Information
2. National Institute on Aging — Alzheimer’s Disease Treatment
3. Medicare.gov — Treatments for Alzheimer’s Disease
Related Articles You May Find Helpful
- Memory Loss vs. Dementia in Seniors 2026: How to Tell the Difference
- Medicare Cancer Treatment Coverage 2026: What Seniors Must Know
- NAD+ Supplements for Seniors 2026: The Anti-Aging Molecule Explained
- Potassium for Seniors 2026: Benefits, Deficiency Signs & Best Foods
- Vertigo in Seniors 2026: Causes, Treatment & Fall Prevention Guide
